Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore! Learn More →

Completed NCT03656744

A Study of HTD1801 in Adults With Nonalcoholic Steatohepatitis (NASH) and Type 2 Diabetes Mellitus (T2DM)

Conditions: Fatty Liver, Nonalcoholic, NAFLD, Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis, Digestive System Diseases, Type 2 Diabetes Mellitus (T2DM)

Sex: All

Ages: 18 Years – 75 Years

Healthy volunteers: No

Phase: PHASE2

Enrollment: 101

Sponsor: HighTide Therapeutics (Hong Kong) Limited

Location: Institute for Liver Health Chandler Arizona

Summary

Randomized, double-blind, placebo-controlled, parallel-group study comparing multiple doses of HTD1801 to placebo.

Eligibility Criteria

Inclusion Criteria: * Clinical diagnosis of NASH as assessed by MRI * Clinically documented diagnosis of T2DM * Body mass index (BMI) \>25 kg/m2 Exclusion Criteria: * Liver disease unrelated to NASH * Poorly controlled T2DM or Type 1 Diabetes Mellitus * History of alcohol or substance abuse or dependence * Inability to undergo MRI for any reason * History of significant cardiovascular disease

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT03656744). StuddyBuddy aggregates publicly available trial information.